Center for Emerging Pathogens, Division of Infectious Diseases, New Jersey Medical School, Rutgers Biomedical and Health Sciences University, Newark, New Jersey, USA.
Department of Pathology and Laboratory Medicine, University Hospital, Newark, New Jersey, USA.
J Clin Microbiol. 2017 Oct;55(10):2964-2971. doi: 10.1128/JCM.00466-17. Epub 2017 Jul 26.
is a tier 1 select agent with the potential to quickly cause severe disease. Rapid identification of this pathogen may accelerate treatment and reduce mortality in the event of a bioterrorism attack. We developed a rapid and sensitive assay to detect bacteremia using a system that is suitable for point-of-care testing. A filter-based cartridge that included both sample processing and PCR amplification functions was loaded with all reagents needed for sample processing and multiplex nested PCR. The assay limit of detection (LOD) and dynamic range were determined by spiking DNA into individual PCR mixtures and CFU into human blood. One-milliliter blood samples were added to the filter-based detection cartridge and tested for on a GeneXpert instrument. Assay specificity was determined by testing blood spiked with non-anthrax bacterial isolates or by testing blood samples drawn from patients with concurrent non- bacteremia or nonbacteremic controls. The assay LODs were 5 genome equivalents per reaction and 10 CFU/ml blood for both the Sterne and V1B strains. There was a 6-log dynamic range. Assay specificity was 100% for tests of non- bacterial isolates and patient blood samples. Assay time was less than 90 min. This automated system suitable for point-of-care detection rapidly identifies directly from blood with high sensitivity. This assay might lead to early detection and more rapid therapy in the event of a bioterrorism attack.
是一种具有快速引起严重疾病潜力的 1 级选择剂。这种病原体的快速鉴定可能会加速治疗并降低生物恐怖袭击的死亡率。我们开发了一种快速、灵敏的检测方法,使用适合床边检测的系统检测菌血症。一个基于过滤器的试剂盒,包含样品处理和 PCR 扩增功能,加载了用于样品处理和多重嵌套 PCR 的所有试剂。通过将 DNA 掺入单个 PCR 混合物和 CFU 掺入人血中来确定检测限(LOD)和动态范围。将 1 毫升血样加入基于过滤器的检测试剂盒中,并在 GeneXpert 仪器上测试 。通过测试用非炭疽细菌分离株污染的血液或同时患有非菌血症或非菌血症对照的患者的血液样本来确定检测特异性。Sterne 和 V1B 株的检测 LOD 分别为每个反应 5 个基因组当量和 10 CFU/ml 血液。检测具有 6 个对数动态范围。对于非细菌分离株和患者血液样本的检测,检测特异性为 100%。检测时间少于 90 分钟。这种自动系统适合床边检测,可直接从血液中快速、高灵敏度地识别 。在生物恐怖袭击的情况下,这种检测方法可能会导致早期检测和更快速的治疗。